
ABSTRACT Background Therapeutic apheresis (TA) is a specialized extracorporeal blood purification modality used in the management of complex hematologic, neurologic, and autoimmune diseases. Despite established global guidelines, its utilization in Nigeria remains largely undocumented. This study assessed awareness, technical knowledge, and institutional readiness for TA among Nigerian healthcare professionals. Methods We conducted an open, cross‐sectional online survey of licensed Nigerian healthcare professionals, recruited by convenience and snowball sampling through professional social media networks (WhatsApp, Instagram, X) over a 2‐month period from January 29, 2026, to April 1, 2026. Because recruitment used an open, non‐probability sampling frame, a conventional response rate could not be calculated; of 180 questionnaires received, 155 (86.1%) met pre‐specified completeness and uniqueness criteria and were analyzed. The questionnaire assessed demographics, awareness of TA services, technical knowledge (10‐item assessment based on ASFA guideline domains), and perceived barriers. Results Respondents were predominantly physicians (63.2%; consultants 22.6%, residents 40.6%), practicing mainly in teaching (47.7%) and private (32.9%) hospitals; 51.6% practiced in a single state (Imo State). Awareness of TPE centers was moderate (45.2%, 95% CI: 37.6%–53.1%), and clinical exposure was low (27.7%, 95% CI: 21.3%–35.2%). The mean knowledge score was 5.10 ± 2.44 of 10. Knowledge level was not significantly associated with professional role, years of experience, or institution type (all p > 0.05), with a borderline, nonsignificant difference by specialty ( p = 0.051); nephrology and critical care specialists showed the highest proportion of good knowledge. The leading perceived barriers were lack of equipment (79.4%), poor funding (75.5%), limited awareness (75.5%), and lack of trained personnel (74.2%). Nearly all respondents (95.5%) supported establishing a national TA registry. Conclusion Nigerian healthcare professionals report substantial gaps in TA awareness and technical knowledge alongside strong readiness to support service expansion. These findings, drawn predominantly from a single geopolitical zone, support targeted investment in structured training, equipment and reimbursement pathways, and a coordinated national apheresis registry, while highlighting the need for confirmatory studies with broader geographic and professional representation.
Introduction Hyperlipidemia is a major risk factor for atherosclerotic cardiovascular disease (ASCVD). Although statins are the cornerstone of lipid-lowering therapy, their use may be limited in some patients by adverse effects. This study evaluated the possible impact of non-drug treatment using double-filtration plasmapheresis (DFPP) on CD14+ monocytes and to identify alterations in plasma proteomics after DFPP in patients with hyperlipidemia.Methods Thirty-seven hyperlipidemic patients were enrolled. Mitochondria changes, lipid peroxidation, reactive oxygen species (ROS), and mitochondrial lipid peroxidation were examined. CD14+ monocyte proteins related to ferroptosis were assayed by western blotting, and plasma proteomic changes were measured by data-independent acquisition (DIA).Results In comparison to their levels prior to double-filtration plasmapheresis (DFPP), there was a notable reduction in total cholesterol (TC), total triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), lipoprotein(a) (Lp(a)), and small dense low-density lipoprotein cholesterol (sdLDL) after DFPP. DFPP may attenuate ferroptosis in peripheral blood CD14+ monocytes of patients with hyperlipidemia. Three protein candidates were identified from the DIA dataset.Conclusions DFPP exerts lipid-lowering effects in patients with hyperlipidemia. The ACSL4/LPCAT3/ALOX5 pathway and the three proteins are likely involved in alleviating ferroptosis. Trial Registration: identifier: NCT03491956Conclusions DFPP exerts lipid-lowering effects in patients with hyperlipidemia. The ACSL4/LPCAT3/ALOX5 pathway and the three proteins are likely involved in alleviating ferroptosis. Trial Registration: identifier: NCT03491956
Introduction To develop and validate a 2-h early-warning nomogram for the risk of unplanned discontinuation of continuous renal replacement therapy (CRRT) in elderly intensive care unit (ICU) patients. Methods This study retrospectively enrolled elderly CRRT patients from two tertiary hospitals (2022-2024) via convenience sampling for model development. Predictive performance was assessed using the area under the receiver operating characteristic curve (AUC), calibration plots, and internal validation using 1000 bootstrap resamples, with goodness of fit assessed by the Hosmer-Lemeshow test; an external cohort (Jan-Aug 2025) was used for clinical applicability. Results The unplanned CRRT discontinuation rate reached 27.4% in the modeling cohort and 32.8% in an external temporal validation cohort (n = 247 sessions). Independent predictors included hypotension, therapeutic intervention scoring system (TISS) score, transmembrane pressure (TMP) at 2 h > 86 mmHg, and diagnosis. The model demonstrated robust predictive performance, with an AUC of 0.860 (training) and 0.865 (validation), good calibration (Brier scores: 0.107 internal, 0.127 external), and clinical net benefit across thresholds per decision curve analysis. Conclusions The model demonstrates robust discrimination, calibration, and clinical net benefit, with readily available variables indicating substantial potential for valuable clinical applications.
Introduction Therapeutic apheresis procedures are inadvertently associated with adverse events, either related to the underlying disease or to the procedure itself. This study aims to analyze the various adverse events encountered during therapeutic apheresis procedures.Method This retrospective study analyses adverse events in therapeutic apheresis procedures with reference to the type of procedure, replacement fluid used, patients' age and gender, disease type, and the adverse events encountered. The data were collected and analyzed using the software R. A p-value of less than 0.05 was taken as significant.Result A total of 348 therapeutic apheresis procedures were performed on 127 patients. Adverse events were reported in 54 procedures in 45 patients. Adverse events were significantly higher in the pediatric age group patients and those with neurological diseases, with a strong association between the number of procedures and adverse events.Conclusion This study identified the number of apheresis procedures and patients in the neurology and pediatric age groups as key risk factors for adverse events in therapeutic apheresis. Optimizing preventive strategies and close monitoring will help reduce adverse events in therapeutic apheresis.